ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has received an average rating of “Buy” from the nineteen analysts that are currently covering the company, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and fifteen have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $56.27.
Several brokerages have recently commented on ACAD. ValuEngine raised shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, April 2nd. BidaskClub raised ACADIA Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, June 17th. JPMorgan Chase & Co. upped their price target on ACADIA Pharmaceuticals from $50.00 to $55.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. Cantor Fitzgerald lifted their price objective on shares of ACADIA Pharmaceuticals from $58.00 to $63.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Finally, Citigroup started coverage on shares of ACADIA Pharmaceuticals in a research note on Thursday, March 5th. They set a “buy” rating and a $69.00 target price for the company.
In other news, CEO Stephen Davis sold 6,770 shares of the firm’s stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $49.21, for a total transaction of $333,151.70. Following the transaction, the chief executive officer now directly owns 18,579 shares of the company’s stock, valued at $914,272.59. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, President Srdjan R. Stankovic sold 82,295 shares of ACADIA Pharmaceuticals stock in a transaction dated Friday, June 19th. The shares were sold at an average price of $50.03, for a total transaction of $4,117,218.85. Following the sale, the president now owns 19,885 shares in the company, valued at $994,846.55. The disclosure for this sale can be found here. Insiders sold a total of 396,172 shares of company stock valued at $19,447,802 over the last three months. Corporate insiders own 27.70% of the company’s stock.
Shares of ACADIA Pharmaceuticals stock traded down $2.26 on Friday, hitting $47.93. 14,775,485 shares of the company’s stock traded hands, compared to its average volume of 1,399,501. ACADIA Pharmaceuticals has a 52-week low of $21.56 and a 52-week high of $53.75. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.20 and a current ratio of 7.26. The firm’s 50-day moving average is $49.23 and its 200 day moving average is $44.64.
ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.09). The company had revenue of $90.07 million during the quarter, compared to analyst estimates of $90.76 million. ACADIA Pharmaceuticals had a negative net margin of 64.99% and a negative return on equity of 39.40%. The company’s revenue was up 43.1% on a year-over-year basis. During the same period in the prior year, the company earned ($0.59) earnings per share. On average, analysts expect that ACADIA Pharmaceuticals will post -1.91 EPS for the current fiscal year.
ACADIA Pharmaceuticals Company Profile
ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
Recommended Story: Dividend Stocks – Are They Right For You?
Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.